The grant's principal investigator and director is
"The awards provide additional funding for the UB program while also expanding our HIV pharmacology research to include drug development for hepatitis C and tuberculosis," says Morse.
Morse currently directs the
Some of the funds will be used to support UB's HIV PSL, which has received continuous NIH support since 1987.
The UB PSL contributes to clinical pharmacology studies that investigate new drug treatments and designs and participates in drug interaction research during new drug development programs. The UB PSL operates a bioanalytical laboratory that develops and validates drug assays using innovative applications of liquid chromatography and mass spectrometry.
The new PSL collaborations in ACTG research include pharmaceutical partners such as U.S.-based Merck (
A new, competitive funding supplement was also awarded to the PSL and includes UB's
This project will bring together the PSL's bioanalysis techniques with ILPB's extensive nanoparticle experience to create new nanomedicine formulations that incorporate drugs for tuberculosis using cell-targeted approaches. These approaches deliver medications directly to the site of TB infection in the lungs. The work will be conducted in the IPLB and the CoE's new nanomedicine laboratory in collaboration with
Funding is also included to continue the expansion of the UB PSL Precautionary and Prohibited Medications Database, a pharmacoinformatics database that identifies new clinical pharmacology studies of drug interactions among HIV, HCV and TB drugs during drug development.
It will also integrate new research data with an informatics utility that is based in the CoE's Translational Pharmacology Research Core. This utility is used by NIH investigators for developing new treatment protocols that access the most current drug interaction data available, thus promoting the safety and protection of subjects who participate in these clinical studies.
The NIH funding additionally supports a new
The overall objective of Ma's proposal is to provide advanced training in antiretroviral pharmacogenomics, related to pharmacokinetics and disease modeling in patients with HIV-associated neurocognitive disorders.
The research plan focuses on the development of a model system to improve risk and intervention assessments by integrating genetic data, pharmacokinetics and toxicity, to establish an individualized risk profile of HIV-associated neurocognitive disorders, one of the prevalent co-morbidities in treated individuals.
Morse says he will serve as the primary mentor for Ma's award, along with additional notable mentors Giovanni Schiffitto, MD, from the
TNS 30TagarumaMar-131029-4530779 30TagarumaMar
Most Popular Stories
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Guardian Pressured to Stop NSA Stories: Editor
- Newtown Massacre Heard on 911 Recordings
- New Home Sales Shoot up 25 Percent in October
- U.S. Growth Stayed Steady During Shutdown, Fed Says
- Allstate Seeks to Invest in Minority Firms
- Boehner Blames Obama, Senate for Congressional Inactivity
- CEOs More Optimistic About Economy, Hiring
- Liberty Power Gets Minority Business Nod
- Latin Music Conference Turns 25